[
  {
    "title": "Global Trends in R&D 2025 | IQVIA",
    "url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025",
    "domain": "www.iqvia.com",
    "lang": "en",
    "type": "Trusted",
    "trusted": true,
    "summary": "Explore IQVIA by region\nAs a global community, IQVIA continuously invests and commits to advancing human health.\nAmericas\nEurope\nAsia & Oceania\nMiddle East & Africa\nRegional Thought Leadership\nSOLUTIONS\nResearch & Development\nReal World Evidence\nCommercialization\nSafety & Regulatory Compliance\nTechnologies\nLIFE SCIENCE SEGMENTS\nConsumer Health\nEmerging Biopharma\nGenerics\nMedTech\nPharmaceutical Manufacturers\nHEALTHCARE SEGMENTS\nInformation Partner Services\nFinancial Institutions\nGlobal Health"
  },
  {
    "title": "2026 Life sciences outlook | Deloitte Insights",
    "url": "https://www.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2026-life-sciences-executive-outlook.html",
    "domain": "www.deloitte.com",
    "lang": "en",
    "type": "Trusted",
    "trusted": true,
    "summary": "Article\n•\n11-min read\n•\n09 December 2025\n•\nDeloitte Center for Health Solutions\nUnited States\nUnited States\nUnited States\nSwitzerland\nMalaysia\nIndia\nThe life sciences industry may be increasingly borderless, but confidence does not appear to be. According to Deloitte’s 2026 Life Sciences Outlook Survey, more than 75% of responding biopharma and medtech executives are confident in their own organizations’ financial outlooks for the coming year."
  },
  {
    "title": "2026 Biopharma Outlook Infographic | Key Trends, Launches ...",
    "url": "https://www.evaluate.com/thought-leadership/2026-biopharma-outlook-infographic/",
    "domain": "www.evaluate.com",
    "lang": "en",
    "type": "Trusted",
    "trusted": true,
    "summary": "Biotech is back! But it’s not quite as simple as that.\nAfter years of volatility, the sector heads into 2026 with a renewed sense of possibility, buoyed by resurgent markets, intensified metabolic health competition, and the first tremors of a looming $300bn patent cliff."
  },
  {
    "title": "EY 2025 Biotech Beyond Borders Report: Biopharma",
    "url": "https://www.ey.com/en_us/newsroom/2025/06/ey-2025-biotech-beyond-borders-report-biopharma",
    "domain": "www.ey.com",
    "lang": "en",
    "type": "Trusted",
    "trusted": true,
    "summary": "- Shifting policy environment creates regulatory and funding challenges: Policy changes will continue to cause uncertainty for the broader industry and investors, including NIH funding, FDA’s ability to timely approve products, potential tariff implications, FTC’s challenge to the Intellectual Property (IP) and CMS’ impact on drug pricing with Most Favored Nations policy alongside the IRA rebates."
  },
  {
    "title": "2026 Preview | Pharma Strategy Report | Evaluate",
    "url": "https://www.evaluate.com/thought-leadership/2026-preview/",
    "domain": "www.evaluate.com",
    "lang": "en",
    "type": "Trusted",
    "trusted": true,
    "summary": "2026 Preview: Navigating Pharma’s Critical Year\nThe biopharma sector enters 2026 in qualified recovery. After years of tough financing and investor skepticism, green shoots are appearing, but not everyone benefits from the rebound.\nThis isn’t another boom. The industry emerging from the drought is smarter, leaner, and more selective. For the rally to build momentum, execution matters."
  }
]